Ensaculin Free Base | CAS# 155773-59-4 (free base) | neuronal activator

MedKoo Cat#: 414026 | Name: Ensaculin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ensaculin Free Base is a neuronal activator.

Chemical Structure

Ensaculin Free Base

CAS#155773-59-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414026

Name: Ensaculin Free Base

CAS#: 155773-59-4 (free base)

Chemical Formula: C26H32N2O5

Exact Mass: 452.2311

Molecular Weight: 452.55

Elemental Analysis: C, 69.01; H, 7.13; N, 6.19; O, 17.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

155773-59-4 (free base) 209969-60-8 (HCl)

Synonym

Ensaculin Free Base

IUPAC/Chemical Name

7-Methoxy-6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)-3,4-dimethylcoumarin

InChi Key

FQELZLMTAPJJOL-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H32N2O5/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3/h5-6,8-9,16-17H,7,10-15H2,1-4H3

SMILES Code

O=C1OC2=C(C=C(OCCCN3CCN(C4=CC=CC=C4OC)CC3)C(OC)=C2)C(C)=C1C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 452.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hoerr R, Noeldner M. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. doi: 10.1111/j.1527-3458.2002.tb00220.x. PMID: 12177685; PMCID: PMC6741668. 2: Teismann P, Ferger B. Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate. Brain Res. 2000 Feb 28;857(1-2):165-71. doi: 10.1016/s0006-8993(99)02395-1. PMID: 10700564. 3: Teismann P, Ferger B. Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release. Eur J Pharmacol. 2000 Jun 16;398(2):247-50. doi: 10.1016/s0014-2999(00)00290-9. PMID: 10854836. 4: Hudáčová M, Hamuľaková S, Konkoľová E, Jendželovský R, Vargová J, Ševc J, Fedoročko P, Soukup O, Janočková J, Ihnatova V, Kučera T, Bzonek P, Novakova N, Jun D, Junova L, Korábečný J, Kuča K, Kožurková M. Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells. Int J Mol Sci. 2021 Apr 7;22(8):3830. doi: 10.3390/ijms22083830. PMID: 33917200; PMCID: PMC8068036. 5: Knauber J, Müller WE. Anseculin improves passive avoidance learning of aged mice. Pharmacol Res. 2003 Mar;47(3):225-33. doi: 10.1016/s1043-6618(02)00311-0. PMID: 12591018. 6: Reisner E, Nöldner M, Rossner S, Chatterjee SS, Bigl V, Schliebs R. Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain. Neurosci Lett. 1999 Oct 29;274(3):187-90. doi: 10.1016/s0304-3940(99)00725-9. PMID: 10548421. 7: Winter JC, Helsley SE, Rabin RA. The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component. Pharmacol Biochem Behav. 1998 Jul;60(3):703-7. doi: 10.1016/s0091-3057(98)00043-4. PMID: 9678654. 8: Sourgens H, Hoerr R, Biber A, Steinbrede H, Derendorf H. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J Clin Pharmacol. 1998 Apr;38(4):373-81. doi: 10.1002/j.1552-4604.1998.tb04438.x. PMID: 9590466. 9: Teismann P, Ferger B. In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):337-48. doi: 10.1016/s0278-5846(99)00088-3. PMID: 10800755. 10: Lishko PV, Maximyuk OP, Chatterjee SS, Nöldner M, Krishtal OA. The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist. Neuroreport. 1998 Dec 21;9(18):4193-7. doi: 10.1097/00001756-199812210-00035. PMID: 9926872.